Author

Zare Melyan

Observed institutions: Inserm, Virginia Commonwealth University, SUNY Upstate Medical University, Columbia University Irving Medical Center, University of Oxford, Supernus Pharmaceuticals (United States), University of Southampton, UCL Queen Square Institute of Neurology, University College London, Columbia University

OpenAlex ID: A5112837345

Metabotropic-Mediated Kainate Receptor Regulation of IsAHP and Excitability in Pyramidal Cells

2002 · Zare Melyan, Howard V. Wheal, et al. · Neuron · 218

PDF

Synaptically released glutamate reduces γ-aminobutyric acid (GABA)ergic inhibition in the hippocampus via kainate receptors

1999 · Ming-Yuan Min, Zare Melyan, et al. · Proceedings of the National Academy of Sciences · 122

Metabotropic Regulation of Intrinsic Excitability by Synaptic Activation of Kainate Receptors

2004 · Zare Melyan, Barrie Lancaster, et al. · Journal of Neuroscience · 120

PDF

Differential Expression of Two Distinct Functional Isoforms of Melanopsin (Opn4) in the Mammalian Retina

2009 · Susana S. Pires, Steven Hughes, et al. · Journal of Neuroscience · 100

PDF

Hippocampal Long-Term Potentiation Is Disrupted during Expression and Extinction But Is Restored after Reinstatement of Morphine Place Preference

2014 · George S. Portugal, Ream Al-Hasani, et al. · Journal of Neuroscience · 70

PDF

Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial

2021 · Azmi Nasser, Tesfaye Liranso, et al. · Clinical Therapeutics · 56

Increased Small Conductance Calcium-Activated Potassium Type 2 Channel-Mediated Negative Feedback on N-methyl-D-aspartate Receptors Impairs Synaptic Plasticity Following Context-Dependent Sensitization to Morphine

2013 · Amanda K. Fakira, George S. Portugal, et al. · Biological Psychiatry · 41

Epileptogenic action of caffeine during anoxia in the neonatal rat hippocampus

1999 · Volodymyr Dzhala, Luc Desfreres, et al. · Annals of Neurology · 39

A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHD.

2021 · Azmi Nasser, Tesfaye Liranso, et al. · PubMed Central · 36

Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trials

2021 · Stephen V. Faraone, Roberto Gomeni, et al. · Psychiatry Research · 33

PDF

The Effect of Viloxazine Extended-Release Capsules on Functional Impairments Associated with Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents in Four Phase 3 Placebo-Controlled Trials

2021 · Azmi Nasser, Joseph T Hull, et al. · Neuropsychiatric Disease and Treatment · 23

PDF

Predicting efficacy of viloxazine extended-release treatment in adults with ADHD using an early change in ADHD symptoms: Machine learning Post Hoc analysis of a phase 3 clinical trial

2022 · Stephen V. Faraone, Roberto Gomeni, et al. · Psychiatry Research · 19

PDF

Executive Function Outcome of Treatment with Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Post-Hoc Analysis of Four Randomized Clinical Trials

2021 · Stephen V. Faraone, Roberto Gomeni, et al. · Pediatric Drugs · 17

PDF

A post hoc analysis of the effect of viloxazine extended-release capsules on learning and school problems in children and adolescents with attention-deficit/hyperactivity disorder

2021 · Stephen V. Faraone, Roberto Gomeni, et al. · European Child & Adolescent Psychiatry · 9

PDF

Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson’s disease

2024 · Azmi Nasser, Roberto Gomeni, et al. · Journal of Pharmacokinetics and Pharmacodynamics · 5

PDF

The role of placebo response in the efficacy outcome assessment in viloxazine extended‐release pivotal trials in paediatric subjects with attention‐deficit/hyperactivity disorder

2022 · Azmi Nasser, Roberto Gomeni, et al. · British Journal of Clinical Pharmacology · 2

PDF

“Needle Phobia” in Patients with Parkinson’s Disease (PD) Experiencing OFF Episodes is Uncommon (2356)

2021 · Aldina Imamovic, Zare Melyan, et al. · Neurology · 2

Correction: Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson’s disease

2024 · Azmi Nasser, Roberto Gomeni, et al. · Journal of Pharmacokinetics and Pharmacodynamics

Works count: 19

Citation count: 916

H-index: 13

I10-index: 13